{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:55:21Z","timestamp":1794020121960,"version":"4.8.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jaci.2026.04.002","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T08:18:15Z","timestamp":1775895495000},"page":"1237-1245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Dupilumab therapy in atopic dermatitis when cutaneous lymphoma is suspected: Consensus recommendations from the EORTC Cutaneous Lymphoma Tumour Group"],"prefix":"10.1016","volume":"157","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1161-269X","authenticated-orcid":false,"given":"Joana","family":"Calv\u00e3o","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ad\u00e8le","family":"de Masson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cozzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chalid","family":"Assaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constanze","family":"Jonak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmilia","family":"Hodak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Papadavid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Roccuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Peter","family":"Nicolay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Scarisbrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten H.","family":"Vermeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Bagot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Battistella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo Luis","family":"Ortiz-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Quaglino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Cowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Stadler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Kempf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarida","family":"Gon\u00e7alo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuella","family":"Guenova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2026.04.002_bib1","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.04.002_bib2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.18176\/jiaci.0682","article-title":"Dupilumab: a review of present indications and off-label uses","volume":"32","author":"Mu\u00f1oz-Bellido","year":"2022","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaci.2026.04.002_bib3","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1007\/s12325-024-02810-3","article-title":"Study design of a phase 2\/3 randomized controlled trial of dupilumab in adults with bullous pemphigoid: LIBERTY-BP ADEPT","volume":"41","author":"Murrell","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.jaci.2026.04.002_bib5","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1111\/ajd.14557","article-title":"Real world side-effects of dupilumab: a narrative review","volume":"66","author":"Larney","year":"2025","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaci.2026.04.002_bib6","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ad.2024.10.059","article-title":"Laboratory changes during dupilumab treatment for atopic dermatitis","volume":"116","author":"Flor","year":"2025","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.jaci.2026.04.002_bib7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41572-021-00296-9","article-title":"Cutaneous T cell lymphoma","volume":"7","author":"Dummer","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jaci.2026.04.002_bib8","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/bjd.17258","article-title":"The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients","volume":"181","author":"Scarisbrick","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2026.04.002_bib9","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2021-1-7","article-title":"Selective IL-13 inhibitors for the treatment of atopic dermatitis","volume":"10","author":"Gon\u00e7alves","year":"2021","journal-title":"Drugs Context"},{"key":"10.1016\/j.jaci.2026.04.002_bib10","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2026.04.002_bib11","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2026.04.002_bib12","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1111\/jdv.19987","article-title":"Classifications of cutaneous lymphomas and lymphoproliferative disorders: an update from the EORTC Cutaneous Lymphoma Histopathology Group","volume":"38","author":"Kempf","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2026.04.002_bib13","first-page":"1307","article-title":"Mycosis fungoides and S\u00e9zary syndrome","volume":"19","author":"Jonak","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.jaci.2026.04.002_bib14","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1016\/j.jid.2024.03.022","article-title":"From molecules to microbes: tracing cutaneous T-cell lymphoma pathogenesis through malignant inflammation","volume":"144","author":"Gordon","year":"2024","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2026.04.002_bib15","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3389\/fonc.2019.00300","article-title":"Environmental and other extrinsic risk factors contributing to the pathogenesis of cutaneous T cell lymphoma (CTCL)","volume":"9","author":"Ghazawi","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.jaci.2026.04.002_bib16","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00281-016-0594-9","article-title":"Malignant inflammation in cutaneous T-cell lymphoma\u2014a hostile takeover","volume":"39","author":"Krejsgaard","year":"2017","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.jaci.2026.04.002_bib17","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1038\/s41590-024-02018-1","article-title":"Cutaneous T cell lymphoma atlas reveals malignant TH2 cells supported by a B cell\u2013rich tumor microenvironment","volume":"25","author":"Li","year":"2024","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2026.04.002_bib18","first-page":"1","article-title":"MHC-I upregulation safeguards neoplastic T cells in the skin against NK cell\u2013mediated eradication in mycosis fungoides","volume":"15","author":"Chang","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2026.04.002_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-021-01419-2","article-title":"Single-cell RNA sequencing reveals markers of disease progression in primary cutaneous T-cell lymphoma","volume":"20","author":"Rindler","year":"2021","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jaci.2026.04.002_bib20","first-page":"1","article-title":"Single-cell transcriptomics links malignant T cells to the tumor immune landscape in cutaneous T cell lymphoma","volume":"13","author":"Liu","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2026.04.002_bib21","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood.2024024817","article-title":"Genetic alteration of class I HLA in cutaneous T-cell lymphoma","volume":"145","author":"Kwang","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2026.04.002_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cells13070584","article-title":"The role of cytokines in cutaneous T cell lymphoma: a focus on the state of the art and possible therapeutic targets","volume":"13","author":"Guglielmo","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.jaci.2026.04.002_bib23","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1159\/000509281","article-title":"Pathogenesis and therapy of primary cutaneous T-cell lymphoma: Collegium Internationale Allergologicum (CIA) update 2020","volume":"181","author":"Bobrowicz","year":"2020","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2026.04.002_bib24","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/ng.3356","article-title":"Genomic landscape of cutaneous T cell lymphoma","volume":"47","author":"Choi","year":"2015","journal-title":"Nat Genet"},{"issue":"pt 3","key":"10.1016\/j.jaci.2026.04.002_bib25","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.semcancer.2021.12.003","article-title":"Molecular pathogenesis of cutaneous T cell lymphoma: role of chemokines, cytokines, and dysregulated signaling pathways","volume":"86","author":"Patil","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.jaci.2026.04.002_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.imlet.2024.106871","article-title":"Pathophysiology of cutaneous T-cell lymphomas: perspective from a French referral centre","volume":"268","author":"De Masson","year":"2024","journal-title":"Immunol Lett"},{"key":"10.1016\/j.jaci.2026.04.002_bib27","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1158\/1078-0432.CCR-12-3488","article-title":"TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma","volume":"19","author":"Guenova","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaci.2026.04.002_bib28","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3390\/life14020245","article-title":"Role of IL-4 and IL-13 in cutaneous T cell lymphoma","volume":"14","author":"Mazzetto","year":"2024","journal-title":"Life"},{"key":"10.1016\/j.jaci.2026.04.002_bib29","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood-2014-07-590398","article-title":"Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation","volume":"125","author":"Geskin","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2026.04.002_bib30","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.4161\/15384101.2014.965061","article-title":"Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression","volume":"13","author":"Netchiporouk","year":"2014","journal-title":"Cell Cycle"},{"key":"10.1016\/j.jaci.2026.04.002_bib31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood.2019004256","article-title":"Genetic and epigenetic insights into cutaneous T-cell lymphoma","volume":"139","author":"Tensen","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2026.04.002_bib32","series-title":"Encyclopedia of hormones","first-page":"470","article-title":"Interleukin-13","author":"de Vries","year":"2003"},{"key":"10.1016\/j.jaci.2026.04.002_bib33","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1182\/blood-2015-02-626432","article-title":"IL-13 as a novel growth factor in CTCL","volume":"125","author":"Wasik","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2026.04.002_bib34","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41435-020-0095-7","article-title":"Evolution and function of interleukin-4 receptor signaling in adaptive immunity and neutrophils","volume":"21","author":"Heeb","year":"2020","journal-title":"Genes Immun"},{"key":"10.1016\/j.jaci.2026.04.002_bib35","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s13555-025-01352-y","article-title":"Interleukin-4 and atopic dermatitis: why does it matter? A narrative review","volume":"15","author":"Torres","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jaci.2026.04.002_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2023.1258823","article-title":"Type 2 cytokines sensitize human sensory neurons to itch-associated stimuli","volume":"16","author":"Mack","year":"2023","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.jaci.2026.04.002_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.878365","article-title":"Recent advances in IL-13R\u03b12\u2013directed cancer immunotherapy","volume":"13","author":"Knudson","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2026.04.002_bib38","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/j.jid.2024.03.019","article-title":"Targeting TGF-\u03b2 activation in cutaneous T-cell lymphomas","volume":"144","author":"Giustiniani","year":"2024","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2026.04.002_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188802","article-title":"Interleukin 13 receptor alpha 2 (IL13R\u03b12): expression, signaling pathways and therapeutic applications in cancer","volume":"1877","author":"Ja\u00e9n","year":"2022","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.jaci.2026.04.002_bib40","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nm1332","article-title":"IL-13 signaling through the IL-13\u03b12 receptor is involved in induction of TGF-\u03b21 production and fibrosis","volume":"12","author":"Fichtner-Feigl","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2026.04.002_bib41","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.str.2010.01.003","article-title":"Molecular basis for shared cytokine recognition revealed in the structure of an unusually high affinity complex between IL-13 and IL-13R\u03b12","volume":"18","author":"Lupardus","year":"2010","journal-title":"Structure"},{"key":"10.1016\/j.jaci.2026.04.002_bib42","doi-asserted-by":"crossref","first-page":"740","DOI":"10.2174\/156652409788970652","article-title":"The signaling function of the IL-13R\u03b12 receptor in the development of gastrointestinal fibrosis and cancer surveillance","volume":"9","author":"Strober","year":"2009","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.jaci.2026.04.002_bib43","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2340\/actadv.v102.2234","article-title":"Development of nodular lesions after dupilumab therapy in erythrodermic mycosis fungoides with interleukin-13 receptor alpha2 expression","volume":"102","author":"Hashimoto","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2026.04.002_bib44","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/j.jaci.2024.10.028","article-title":"Integrative epidemiology and immunotranscriptomics uncover a risk and potential mechanism for cutaneous lymphoma unmasking or progression with dupilumab therapy","volume":"155","author":"Cabrera-Perez","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.04.002_bib45","doi-asserted-by":"crossref","first-page":"131","DOI":"10.12788\/cutis.0066","article-title":"Cutaneous T-cell lymphoma and concomitant atopic dermatitis responding to dupilumab","volume":"106","author":"Mollanazar","year":"2020","journal-title":"Cutis"},{"key":"10.1016\/j.jaci.2026.04.002_bib46","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/jdv.17001","article-title":"Rapid and sustained control of itch and reduction in Th2 bias by dupilumab in a patient with S\u00e9zary syndrome","volume":"35","author":"Steck","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2026.04.002_bib47","first-page":"E8","article-title":"Long-standing dermatitis treated with dupilumab with subsequent progression to cutaneous T-cell lymphoma","volume":"106","author":"Claire Hollins","year":"2020","journal-title":"Cutis"},{"key":"10.1016\/j.jaci.2026.04.002_bib48","doi-asserted-by":"crossref","first-page":"e13880","DOI":"10.1111\/dth.13880","article-title":"Progression of mycosis fungoides after treatment with dupilumab: a case report","volume":"33","author":"Miyashiro","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaci.2026.04.002_bib49","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jdcr.2020.12.010","article-title":"Acceleration of cutaneous T-cell lymphoma following dupilumab administration","volume":"8","author":"Russomanno","year":"2021","journal-title":"JAAD Case Reports"},{"key":"10.1016\/j.jaci.2026.04.002_bib50","doi-asserted-by":"crossref","DOI":"10.5070\/D3264048364","article-title":"Development of S\u00e9zary syndrome following the administration of dupilumab","volume":"26","author":"Tran","year":"2020","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.jaci.2026.04.002_bib51","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/ced.15079","article-title":"Dupilumab unmasking cutaneous T-cell lymphoma: report of a fatal case","volume":"47","author":"Poyner","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaci.2026.04.002_bib52","doi-asserted-by":"crossref","first-page":"818","DOI":"10.2340\/00015555-3208","article-title":"Diagnosis of mycosis fungoides following administration of dupilumab for misdiagnosed atopic dermatitis","volume":"99","author":"Chiba","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2026.04.002_bib53","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jaad.2020.03.050","article-title":"Progression of cutaneous T-cell lymphoma after dupilumab: case review of 7 patients","volume":"83","author":"Espinosa","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2026.04.002_bib54","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.jaad.2024.10.119","article-title":"Cutaneous T cell lymphoma arising in patients treated with dupilumab: a case series of 18 patients","volume":"92","author":"Accetta","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2026.04.002_bib55","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1007\/s00403-023-02652-z","article-title":"Dupilumab-associated mycosis fungoides: a cross-sectional study","volume":"315","author":"Hamp","year":"2023","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaci.2026.04.002_bib56","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jaad.2024.03.039","article-title":"Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study","volume":"91","author":"Hasan","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2026.04.002_bib57","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.jaad.2024.08.057","article-title":"Decoupling the association of dupilumab with cutaneous T-cell lymphoma. Reply to: Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study","volume":"91","author":"Neubauer","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2026.04.002_bib58","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1111\/jdv.20141","article-title":"Cutaneous T-cell lymphoma and dupilumab use: a retrospective matched cohort study of clinical characteristics and treatment outcomes","volume":"39","author":"Stuver","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2026.04.002_bib59","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1016\/j.jaad.2024.06.091","article-title":"Response to: Hasan et al, Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study","volume":"91","author":"Wu","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2026.04.002_bib60","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jaad.2015.02.1116","article-title":"Risk of lymphoma in atopic dermatitis: a systematic review and metaanalysis of epidemiologic studies","volume":"72","author":"Legendre","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2026.04.002_bib61","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/bjd\/ljad072","article-title":"Malignancy risk in patients with atopic dermatitis: a population-based cohort study","volume":"189","author":"Wan","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2026.04.002_bib62","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1001\/jamadermatol.2020.1948","article-title":"Association between atopic eczema and cancer in England and Denmark","volume":"156","author":"Mansfield","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2026.04.002_bib63","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jid.2024.08.015","article-title":"Cutaneous T-cell lymphoma and dupilumab use: a multifactorial and complex story","volume":"145","author":"Beylot-Barry","year":"2024","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2026.04.002_bib64","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1001\/jamadermatol.2023.3849","article-title":"Dupilumab-associated lymphoid reactions in patients with atopic dermatitis","volume":"159","author":"Boesjes","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2026.04.002_bib65","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1097\/DAD.0000000000001875","article-title":"Evolution of dupilumab-associated cutaneous atypical lymphoid infiltrates","volume":"43","author":"Sokumbi","year":"2021","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.jaci.2026.04.002_bib66","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1111\/jdv.20053","article-title":"Detecting T-cell receptor clonality in patients with severe atopic dermatitis refractory to dupilumab","volume":"38","author":"Kook","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2026.04.002_bib67","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.jaad.2024.06.104","article-title":"Response to: Hasan et al, Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study","volume":"92","author":"Flynn","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2026.04.002_bib68","article-title":"Comments on: Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T-cell lymphoma: a retrospective cohort study","volume":"91","author":"Cho","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2026.04.002_bib69","article-title":"Case report: cutaneous T-cell lymphoma associated with biologic therapy: three cases and a literature review","volume":"12","author":"Li","year":"2025","journal-title":"Front Med"},{"key":"10.1016\/j.jaci.2026.04.002_bib70","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.jaad.2025.01.088","article-title":"Diagnosis of cutaneous T-cell lymphoma following exposure to biologic agents for atopic dermatitis: a retrospective cohort study from a single tertiary cancer center","volume":"92","author":"Liao","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2026.04.002_bib71","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jdcr.2025.03.030","article-title":"Mycosis fungoides unmasked by tralokinumab treatment for atopic dermatitis","volume":"61","author":"Basrai","year":"2025","journal-title":"JAAD Case Reports"},{"key":"10.1016\/j.jaci.2026.04.002_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdcr.2025.11.057","article-title":"Mycosis fungoides unmasked during lebrikizumab treatment","author":"Yoon","year":"2026","journal-title":"JAAD Case Reports"},{"key":"10.1016\/j.jaci.2026.04.002_bib73","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s40257-023-00792-6","article-title":"Safety of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis: an integrated analysis of eight clinical trials","volume":"24","author":"Stein Gold","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaci.2026.04.002_bib74","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s13555-023-00942-y","article-title":"Safety and efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: a 52-week, open-label, phase 3 study","volume":"13","author":"Paller","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jaci.2026.04.002_bib75","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/cea.70136","article-title":"New topical and systemic treatments for atopic dermatitis","volume":"55","author":"Mirali","year":"2025","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2026.04.002_bib76","doi-asserted-by":"crossref","DOI":"10.1177\/03000605241286832","article-title":"IL-13 inhibition in the treatment of atopic dermatitis\u2014new and emerging biologic agents","volume":"52","author":"Teixeira","year":"2024","journal-title":"J Int Med Res"},{"key":"10.1016\/j.jaci.2026.04.002_bib77","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s13555-023-00947-7","article-title":"Binding, neutralization and internalization of the interleukin-13 antibody, lebrikizumab","volume":"13","author":"Okragly","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jaci.2026.04.002_bib78","doi-asserted-by":"crossref","first-page":"13388","DOI":"10.3390\/ijms222413388","article-title":"Safety and danger considerations of novel treatments for atopic dermatitis in context of primary cutaneous lymphomas","volume":"22","author":"Ko\u0142kowski","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaci.2026.04.002_bib79","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s40257-025-00955-7","article-title":"Cutaneous T cell lymphoma following dupilumab therapy in patients with atopic dermatitis: clinical review and recommendations","volume":"26","author":"Lavin","year":"2025","journal-title":"Am J Clin Dermatol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009167492600254X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009167492600254X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T09:56:27Z","timestamp":1780566987000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009167492600254X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":78,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S009167492600254X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2026.04.002","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dupilumab therapy in atopic dermatitis when cutaneous lymphoma is suspected: Consensus recommendations from the EORTC Cutaneous Lymphoma Tumour Group","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2026.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}